



Manhattan Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Techvest Global Healthcare Conference

Manhattan Pharmaceuticals, Inc. to Present at the Rodman & Renshaw Techvest Global Healthcare Conference

New York NY, April 28, 2005 -- Manhattan Pharmaceuticals, Inc. ("Manhattan" OTCBB: MHTT), has accepted an invitation to speak at the Rodman & Renshaw Techvest Global Healthcare Conference at 9:05 A.M. CEST (3:05 AM EDT) Wednesday, May 4th, at the Intercontinental Hotel in Paris. Manhattan is one of 160 public and private emerging growth biotechnology companies scheduled to present at the conference. Doug Abel, President and CEO of Manhattan Pharmaceuticals, will provide a company overview, an update on its current clinical development programs and recent acquisition of Tarpan Therapeutics.

The presentation will be webcast live and archived online on the Investor Relations section of Manhattan's website at www.manhattanpharma.com. An audio replay of the presentation will also be available for 90 days after the conference.

About Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc. (<http://www.manhattanpharma.com/>), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the Company is developing Oleoyl estrone, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, under development for psoriasis and other dermatological conditions and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.